Xencor
Develops superior monoclonal antibody therapeutics to treat autoimmune disorders, asthma, allergic diseases and cancer.
Launch date
Employees
Market cap
€1.4b
Enterprise valuation
€982m (Public information from Sep 2024)
Share price
$21.2 XNCR
Monrovia California (HQ)
Authorizing premium user...